Spondyloarthritis & psoriatic arthritis
Site-specific articular response to TNF inhibitor in axial spondyloarthritis: A European cohort study
Authors' conclusion
The peripheral joint response to TNFi in axSpA appears to be location-dependent
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) from EuroSpA RCN initiating a tumour necrosis factor inhibitors (TNFi) 2001–2022, with ≥1 tender joint at baseline (26-joint count)5,886 tender joints
- Participants
- 1,113 patients
- Exposure
- Joint tenderness resolution by joint site vs wrist
- Outcome
- Resolution of joint tenderness
- Follow-up
- two-year follow-up
Methodological detailsmultinational (eight European countries), mixed-effects model for interval-censored data, random effects for country and patient
- Multinational (eight European countries)
- Mixed-effects model for interval-censored data
- Random effects for country and patient
Main finding
As reported in the abstract
Rate of joint tenderness resolution by joint site, compared with the wrist
Each group vs wristHR for joint tenderness resolution (95% CI)
Elbow
1.06(0.88–1.28)
Knee
0.76(0.64–0.90)
First interphalangeal joint
2.64(2.05–3.40)
Metacarpophalangeal joint (MCP)4
2.19(1.77–2.71)
MCP5
3.16(2.50–4.00)
Observational data: associations, not effects.
Further findings
Most commonly affected joints at baseline
- The knee and wrist were most commonly affected at baseline
Original publication
Site-specific articular response to TNF inhibitor in axial spondyloarthritis: A European cohort study. Joint Bone Spine. Published 24 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →